New insomnia drug HS-10506 put to the test in large safety trial
NCT ID NCT07677384
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 3 study evaluates the safety of HS-10506, an experimental insomnia medication, in 600 Chinese adults aged 18 to 64 with insomnia disorder. Researchers track side effects, serious adverse events, and specific safety concerns over both short and long-term use. The goal is to determine whether HS-10506 is safe enough for broader use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HS-10506
- What this could lead to
- If safe and effective, HS-10506 could offer a new treatment option for insomnia, potentially improving sleep without serious side effects.
- What could go wrong
- This trial focuses on safety, not effectiveness, and results may not apply to non-Chinese populations. Side effects are possible, and the drug may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSOMNIA DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sleep clinic study aims to uncover best practices for treating insomnia and body clock disorders
- Can a sleep app help save teens from suicide?
- New sleep aid YZJ-1139 put to the test in large trial
- New sleep aid aims to outperform standard insomnia treatment
- One yoga session may boost heart health overnight
- Can a pill help kids with insomnia sleep better?